Drug Overdose - Pipeline Review, H2 2020
Drug Overdose - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H2 2020, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.
Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 2, 3, 5, 3 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H2 2020, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.
Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 2, 3, 5, 3 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Drug Overdose - Overview
Drug Overdose - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corp
Amphastar Pharmaceuticals Inc
Crossject SA
Emergent BioSolutions Inc
Fab’entech SA
Icure Pharmaceutical Inc
Insys Therapeutics Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Opiant Pharmaceuticals Inc
Orexo AB
PledPharma AB
ResQ Pharma Inc
Vallon Pharmaceuticals Inc
Worphmed Srl
Drug Overdose - Drug Profiles
Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
drinabant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXTf-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone. - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPNT-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
physostigmine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Substance Abuse and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug Overdose - Dormant Projects
Drug Overdose - Discontinued Products
Drug Overdose - Product Development Milestones
Featured News & Press Releases
Aug 17, 2020: Emergent BioSolutions announces FDA approval of NARCAN (naloxone HCl) nasal spray shelf life extension to 36 months
Jul 01, 2020: Klaria Pharma initiates clinical program for Naloxone Alginate Film to prevent opioid overdose
Jun 30, 2020: Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal
Jun 18, 2020: Adamis Pharmaceuticals announces publication of pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose
Jun 05, 2020: Opiant Pharmaceuticals statement on U.S. District Court decision
May 27, 2020: Adamis Pharmaceuticals announces publication of pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone
May 18, 2020: Adamis Pharmaceuticals resubmits ZIMHI New Drug Application to FDA
Apr 23, 2020: Adamis Pharmaceuticals announces Publication demonstrating PET Scan results of higher dose Naloxone in Monkeys
Dec 19, 2019: Adamis Pharmaceuticals provides an update on ZIMHI
Dec 12, 2019: Opiant Pharmaceuticals announces contract extension of second tranche of approximately $2.4 million from Biomedical Advanced Research and Development Authority for development of OPNT003, Nasal Nalmefene, for the treatment of Opioid Overdose
Nov 26, 2019: FDA rejects Adamis’ NDA for high-dose naloxone against opioid overdose
Nov 18, 2019: Adamis Pharmaceuticals announces publication of comparative pharmacokinetics of community use naloxone formulations
Nov 04, 2019: Adamis Pharmaceuticals provides regulatory update for its higher dose Naloxone Pre-Filled Syringe
Oct 08, 2019: Adamis Pharmaceuticals announces presentation of ZIMHI data at IHV Scientific Meeting
Sep 26, 2019: Adamis Pharmaceuticals announces presentation pertaining to its high dose naloxone product candidate at IHV Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Drug Overdose - Overview
Drug Overdose - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Drug Overdose - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Overdose - Companies Involved in Therapeutics Development
Adamis Pharmaceuticals Corp
Amphastar Pharmaceuticals Inc
Crossject SA
Emergent BioSolutions Inc
Fab’entech SA
Icure Pharmaceutical Inc
Insys Therapeutics Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Opiant Pharmaceuticals Inc
Orexo AB
PledPharma AB
ResQ Pharma Inc
Vallon Pharmaceuticals Inc
Worphmed Srl
Drug Overdose - Drug Profiles
Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
drinabant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXTf-250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone. - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPNT-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
physostigmine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Substance Abuse and Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Drug Overdose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug Overdose - Dormant Projects
Drug Overdose - Discontinued Products
Drug Overdose - Product Development Milestones
Featured News & Press Releases
Aug 17, 2020: Emergent BioSolutions announces FDA approval of NARCAN (naloxone HCl) nasal spray shelf life extension to 36 months
Jul 01, 2020: Klaria Pharma initiates clinical program for Naloxone Alginate Film to prevent opioid overdose
Jun 30, 2020: Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal
Jun 18, 2020: Adamis Pharmaceuticals announces publication of pharmacokinetic model suggesting that higher doses of naloxone are needed for successful resuscitation due to fentanyl overdose
Jun 05, 2020: Opiant Pharmaceuticals statement on U.S. District Court decision
May 27, 2020: Adamis Pharmaceuticals announces publication of pharmacokinetic study comparing ZIMHI to current 2 mg intramuscular dose of naloxone
May 18, 2020: Adamis Pharmaceuticals resubmits ZIMHI New Drug Application to FDA
Apr 23, 2020: Adamis Pharmaceuticals announces Publication demonstrating PET Scan results of higher dose Naloxone in Monkeys
Dec 19, 2019: Adamis Pharmaceuticals provides an update on ZIMHI
Dec 12, 2019: Opiant Pharmaceuticals announces contract extension of second tranche of approximately $2.4 million from Biomedical Advanced Research and Development Authority for development of OPNT003, Nasal Nalmefene, for the treatment of Opioid Overdose
Nov 26, 2019: FDA rejects Adamis’ NDA for high-dose naloxone against opioid overdose
Nov 18, 2019: Adamis Pharmaceuticals announces publication of comparative pharmacokinetics of community use naloxone formulations
Nov 04, 2019: Adamis Pharmaceuticals provides regulatory update for its higher dose Naloxone Pre-Filled Syringe
Oct 08, 2019: Adamis Pharmaceuticals announces presentation of ZIMHI data at IHV Scientific Meeting
Sep 26, 2019: Adamis Pharmaceuticals announces presentation pertaining to its high dose naloxone product candidate at IHV Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Drug Overdose, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Drug Overdose - Pipeline by Adamis Pharmaceuticals Corp, H2 2020
Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Crossject SA, H2 2020
Drug Overdose - Pipeline by Emergent BioSolutions Inc, H2 2020
Drug Overdose - Pipeline by Fab’entech SA, H2 2020
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, H2 2020
Drug Overdose - Pipeline by Insys Therapeutics Inc, H2 2020
Drug Overdose - Pipeline by InterveXion Therapeutics LLC, H2 2020
Drug Overdose - Pipeline by Klaria Pharma Holding AB, H2 2020
Drug Overdose - Pipeline by Mucodel Pharma LLC, H2 2020
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Orexo AB, H2 2020
Drug Overdose - Pipeline by PledPharma AB, H2 2020
Drug Overdose - Pipeline by ResQ Pharma Inc, H2 2020
Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Worphmed Srl, H2 2020
Drug Overdose - Dormant Projects, H2 2020
Drug Overdose - Discontinued Products, H2 2020
Number of Products under Development for Drug Overdose, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Drug Overdose - Pipeline by Adamis Pharmaceuticals Corp, H2 2020
Drug Overdose - Pipeline by Amphastar Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Crossject SA, H2 2020
Drug Overdose - Pipeline by Emergent BioSolutions Inc, H2 2020
Drug Overdose - Pipeline by Fab’entech SA, H2 2020
Drug Overdose - Pipeline by Icure Pharmaceutical Inc, H2 2020
Drug Overdose - Pipeline by Insys Therapeutics Inc, H2 2020
Drug Overdose - Pipeline by InterveXion Therapeutics LLC, H2 2020
Drug Overdose - Pipeline by Klaria Pharma Holding AB, H2 2020
Drug Overdose - Pipeline by Mucodel Pharma LLC, H2 2020
Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Orexo AB, H2 2020
Drug Overdose - Pipeline by PledPharma AB, H2 2020
Drug Overdose - Pipeline by ResQ Pharma Inc, H2 2020
Drug Overdose - Pipeline by Vallon Pharmaceuticals Inc, H2 2020
Drug Overdose - Pipeline by Worphmed Srl, H2 2020
Drug Overdose - Dormant Projects, H2 2020
Drug Overdose - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Drug Overdose, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Adamis Pharmaceuticals Corp
Amphastar Pharmaceuticals Inc
Crossject SA
Emergent BioSolutions Inc
Fab’entech SA
Icure Pharmaceutical Inc
Insys Therapeutics Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Opiant Pharmaceuticals Inc
Orexo AB
PledPharma AB
ResQ Pharma Inc
Vallon Pharmaceuticals Inc
Worphmed Srl
Number of Products under Development for Drug Overdose, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
COMPANIES MENTIONED
Adamis Pharmaceuticals Corp
Amphastar Pharmaceuticals Inc
Crossject SA
Emergent BioSolutions Inc
Fab’entech SA
Icure Pharmaceutical Inc
Insys Therapeutics Inc
InterveXion Therapeutics LLC
Klaria Pharma Holding AB
Mucodel Pharma LLC
Opiant Pharmaceuticals Inc
Orexo AB
PledPharma AB
ResQ Pharma Inc
Vallon Pharmaceuticals Inc
Worphmed Srl
